Suggested remit - To appraise the clinical and cost effectiveness of pembrolizumab with chemotherapy within its marketing authorisation for treating advanced or metastatic urothelial cancer
Following on from information provided to NICE by the company in July 2020 the appraisal of Pembrolizumab with chemotherapy for treating advanced or metastatic urothelial cancer [ID1545] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
- Status:
- Discontinued
- Technology type:
- Medicine
- Decision:
- Prioritised
- Process:
- TA
- ID number:
- 1545
Email enquiries
If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 15 November 2022 | Note added to the project documents |
| 15 November 2022 | Discontinued. Following on from information provided to NICE by the company in July 2020 the appraisal of Pembrolizumab with chemotherapy for treating advanced or metastatic urothelial cancer [ID1545] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 06 July 2020 | Note added to the project documents |
| 06 July 2020 | Suspended. Topic is suspended |
| 11 September 2019 | Note added to the project documents |
| 10 June 2019 | Note added to the project documents |
| 15 April 2019 - 16 May 2019 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
| 17 October 2018 | In progress. Topic referred |
For further information on our processes and methods, please see our CHTE processes and methods manual